Holen Sie sich die Stockscreener-App
251.95
0.53%
-1.34
Handel nachbörslich:
251.93
-0.02
-0.01%
Schlusskurs vom Vortag:
$253.29
Offen:
$256.35
24-Stunden-Volumen:
329.92K
Relative Volume:
0.50
Marktkapitalisierung:
$16.53B
Einnahmen:
$1.01B
Nettoeinkommen (Verlust:
$581.90M
KGV:
28.39
EPS:
8.8733
Netto-Cashflow:
$50.57M
1W Leistung:
+1.84%
1M Leistung:
-0.75%
6M Leistung:
+7.22%
1J Leistung:
+29.67%
1-Tages-Spanne:
$247.03
$256.35
1-Wochen-Bereich:
$245.68
$261.61
52-Wochen-Spanne:
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Firmenname
Ascendis Pharma A S
Sektor
Branche
Telefon
-
Adresse
-
Compare ASND vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
251.95 | 16.71B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-17 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Eingeleitet | Stifel | Buy |
| 2023-12-20 | Eingeleitet | Jefferies | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Neutral |
| 2023-04-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-08-30 | Fortgesetzt | Berenberg | Buy |
| 2022-03-28 | Fortgesetzt | Wedbush | Outperform |
| 2022-03-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Market Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-30 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Fortgesetzt | Stifel | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2019-01-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Eingeleitet | Stifel | Buy |
| 2018-04-02 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2017-03-09 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Eingeleitet | Credit Suisse | Outperform |
| 2016-09-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine - Yahoo Finance
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript - AOL.com
Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress? - Yahoo Finance
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets - MarketBeat
Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced? - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis a new outperform at BMO on TransCon platform growth - Seeking Alpha
Penn Series Small Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BMO initiates Ascendis Pharma stock coverage with outperform rating By Investing.com - Investing.com Nigeria
BMO initiates Ascendis Pharma stock coverage with outperform rating - Investing.com
BMO Capital Initiates Ascendis Pharma at Outperform - marketscreener.com
Ascendis Pharma (ASND) Reports Positive Phase 2 Achondroplasia Data As Pivotal Trial Enrollment Ends - Sahm
Why Is Nasdaq Watching Ascendis Pharma (NASDAQ:ASND) Endocrine Drugs? - Kalkine Media
Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock - MarketBeat
Ascendis Pharma (NASDAQ: ASND) director adds 2,000 shares - Stock Titan
Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common shares - Bitget
Ascendis Pharma A/S (ASND) Stock Analysis: Healthcare Innovator with a 25% Upside Potential - DirectorsTalk Interviews
symbol__ Stock Quote Price and Forecast - CNN
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $275 to $360 - Moomoo
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen - MarketBeat
Allspring Emerging Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth - simplywall.st
Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS - MarketBeat
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call - Sahm
Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital. - Pluang
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says - marketscreener.com
RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating - marketscreener.com
Ascendis Pharma doubles sales, significantly boosting profit - medwatch.com
Ascendis Pharma AS earnings beat by €1.32, revenue topped estimates - Investing.com Nigeria
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Re - GuruFocus
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ... - Yahoo Finance
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength By Investing.com - Investing.com South Africa
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength - Investing.com Nigeria
Artisan Partners (ASND holder) discloses 2.63M Ascendis Pharma shares in 13G/A - Stock Titan
Ascendis Pharma's Long-Term Potential Intact, Wedbush Says - marketscreener.com
Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost - Quiver Quantitative
Ascendis Pharma A/S Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ascendis Pharma tops Q2 2026 estimates as launches gain - Investing.com
ASND: Q2 revenue more than doubled year-over-year, fueled by strong TransCon product demand and robust launches - TradingView
Ascendis Pharma A/S reports results for the quarter ended June 30Earnings Summary - TradingView
Ascendis Pharma (ASND) posts Q2 2026 profit on revenue surge and PRV sale - Stock Titan
Ascendis Pharma: Product Revenue Surges 105% To €315 Million As Adjusted Operating Profit Turns Positive - Pulse 2.0
Ascendis Pharma A/S Q2 2026 Earnings Call Transcript - MarketBeat
Ascendis Pharma's Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
Ascendis Pharma (ASND) posts €836M H1 profit and redeems $575M converts - Stock Titan
Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale - TradingView
Earnings Flash (ASND) Ascendis Pharma Posts Q2 Non-IFRS EPS 0.90 Euros, vs. FactSet Est of 1.80 Euros - marketscreener.com
Ascendis Pharma Reports Second Quarter 2026 Financial Results - The Manila Times
Ascendis Pharma Reports More Than 220 U.S. YUVIWEL Enrollments - Stock Titan
Finanzdaten der Ascendis Pharma A S-Aktie (ASND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ascendis Pharma A S-Aktie (ASND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
Jun 02 '26 |
Buy |
219.00 |
100 |
21,900 |
4,367 |
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):